Boundless Bio Inc (BOLD) Q4 2025 Earnings Call Transcript

Why It Matters

The explosive top‑line growth and emerging profitability signal Biodesix’s ability to scale personalized lung diagnostics, positioning it for sustained market share gains and potential long‑term earnings upside.

Key Takeaways

• Revenue $88.5M, up 4,124% YoY
• Lung diagnostics drive 4,622% revenue surge
• Primary care test share 12%, up 67%
• Adjusted EBITDA positive $0.53M, first quarter
• Guidance 2026 revenue $106‑112M, 23% growth

Pulse Analysis

Biodesix closed fiscal 2025 with $88.5 million in revenue, a staggering 4,124 % increase year‑over‑year, propelled primarily by its lung‑diagnostics franchise. Gross margins climbed to 83 % in Q4, reflecting scale efficiencies and workflow optimization, while operating expenses rose sharply as the company invested in sales and R&D. The most notable profitability milestone was a positive adjusted EBITDA of $530 k for the quarter, the first such result in the company’s history. A strengthened balance sheet, now bolstered by $33.7 million of pro‑forma cash and an additional $14.7 million of ATM proceeds, gives Biodesix ample runway for continued growth.

The surge in top‑line performance stems from an aggressive commercial push that extended Nodify testing beyond interventional pulmonologists into primary‑care settings, where test volume grew 67 % and now represents 12 % of total orders. The field force expanded to 97 representatives, with a plan to add six reps each quarter in 2026, enhancing market penetration across both pulmonology and primary‑care channels. Strategic collaborations with Thermo Fisher Scientific and Bio‑Rad Laboratories further validate Biodesix’s multi‑omic platform and open new avenues for development services, which posted 1,241 % revenue growth in the year.

Looking ahead, management projected 2026 revenue between $106 million and $112 million, implying roughly 23 % mid‑point growth, and expects adjusted EBITDA to remain positive as the enlarged sales organization gains tenure. The pipeline includes a next‑generation MRD assay, expanded VeriStrat indications, an ESR1 genomic test, and an AI‑driven digital diagnostic, all positioned to diversify revenue streams beyond lung cancer. Investors should weigh the company’s rapid top‑line expansion against the sizable expense base and the seasonal headwinds noted for early‑year quarters. Continued payer acceptance and real‑world evidence will be critical to sustaining margin expansion and achieving long‑term profitability.